Search: onr:"swepub:oai:DiVA.org:su-145997" >
Engineered botulinu...
Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors
-
Tao, Liang (author)
-
Peng, Lisheng (author)
-
- Berntsson, Ronnie P. -A. (author)
- Umeå universitet,Stockholms universitet,Institutionen för biokemi och biofysik,Umeå University, Sweden,Institutionen för medicinsk kemi och biofysik,Department of Biochemistry and Biophysics, Stockholm University, Stockholm, Sweden
-
show more...
-
Liu, Sai Man (author)
-
Park, SunHyun (author)
-
Yu, Feifan (author)
-
Boone, Christopher (author)
-
Palan, Shilpa (author)
-
Beard, Matthew (author)
-
Chabrier, Pierre-Etienne (author)
-
- Stenmark, Pål (author)
- Stockholms universitet,Institutionen för biokemi och biofysik
-
Krupp, Johannes (author)
-
Dong, Min (author)
-
show less...
-
(creator_code:org_t)
- 2017-07-03
- 2017
- English.
-
In: Nature Communications. - : Springer Science and Business Media LLC. - 2041-1723. ; 8
- Related links:
-
https://doi.org/10.1...
-
show more...
-
https://www.nature.c...
-
https://umu.diva-por... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
show less...
Abstract
Subject headings
Close
- Botulinum neurotoxin B is a Food and Drug Administration-approved therapeutic toxin. However, it has lower binding affinity toward the human version of its major receptor, synaptotagmin II (h-Syt II), compared to mouse Syt II, because of a residue difference. Increasing the binding affinity to h-Syt II may improve botulinum neurotoxin B's therapeutic efficacy and reduce adverse effects. Here we utilized the bacterial adenylate cyclase two-hybrid method and carried out a saturation mutagenesis screen in the Syt II-binding pocket of botulinum neurotoxin B. The screen identifies E1191 as a key residue: replacing it with M/C/V/Q enhances botulinum neurotoxin B binding to human synaptotagmin II. Adding S1199Y/W or W1178Q as a secondary mutation further increases binding affinity. Mutant botulinum neurotoxin B containing E1191M/S1199Y exhibits similar to 11-fold higher efficacy in blocking neurotransmission than wild-type botulinum neurotoxin B in neurons expressing human synaptotagmin II, demonstrating that enhancing receptor binding increases the overall efficacy at functional levels. The engineered botulinum neurotoxin B provides a platform to develop therapeutic toxins with improved efficacy.
Subject headings
- NATURVETENSKAP -- Biologi (hsv//swe)
- NATURAL SCIENCES -- Biological Sciences (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinsk bioteknologi -- Medicinsk bioteknologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Medical Biotechnology -- Medical Biotechnology (hsv//eng)
Keyword
- Molecular medicine
- Protein design
- Proteins
- Recombinant protein therapy
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Tao, Liang
-
Peng, Lisheng
-
Berntsson, Ronni ...
-
Liu, Sai Man
-
Park, SunHyun
-
Yu, Feifan
-
show more...
-
Boone, Christoph ...
-
Palan, Shilpa
-
Beard, Matthew
-
Chabrier, Pierre ...
-
Stenmark, Pål
-
Krupp, Johannes
-
Dong, Min
-
show less...
- About the subject
-
- NATURAL SCIENCES
-
NATURAL SCIENCES
-
and Biological Scien ...
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Medical Biotechn ...
-
and Medical Biotechn ...
- Articles in the publication
-
Nature Communica ...
- By the university
-
Stockholm University
-
Umeå University